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Background.  Research on the safety and efficacy of continuous lidocaine infusions 83 
(CLIs) for treatment of pain in the pediatric setting is limited.  This manuscript describes a 84 
series of pediatric oncology patients who received lidocaine infusions for refractory, 85 
longstanding, cancer-related pain. 86 
Procedure.  This is a retrospective review of patients who underwent lidocaine 87 
infusions to manage severe, opioid-refractory, cancer-related pain.  Four patients ranging in 88 
age from 8-18 years were admitted to a pediatric hospital for their medical conditions and/or 89 
pain management.  Structured chart review established demographic and diagnosis 90 
information, infusion rates, side effects, and efficacy of infusions in providing pain relief.  91 
Lidocaine bolus doses, infusion rates, serum concentrations, and subjective pain scores were 92 
analyzed.  93 
Results.  Median pain scores prior to lidocaine infusions were 8/10, falling to 2/10 at 94 
the infusion termination (p<0.003), and rising to 3/10 in the first 24 hours after lidocaine 95 
(p<0.029 compared to pre-infusion pain).  The infusions were generally well-tolerated, with 96 
few side effects noted.  In most cases, the improvement in pain scores persisted beyond 97 
termination of the infusion. 98 
Conclusions.  Continuous lidocaine infusions were a helpful adjuvant in the four 99 
cases presented and may be an effective therapy for a more diverse array of refractory cancer 100 
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of the lidocaine, corroborating a modulation effect on pain wind-up.  Additional research 102 
regarding infusion rates, serum concentrations, side effects, and outpatient follow-up in a 103 
larger group of patients will provide additional insight into the role and safety of this therapy 104 
in children. 105 
Introduction 106 
The World Health Organization (WHO) ladder describes an approach to medical 107 
therapies for pain management starting with non-opioid therapies for mild pain, and 108 
progressing to opioid medications for moderate to severe pain. However, in cases of severe or 109 
refractory pain where the use of first-line and opioid therapies is inadequate, ineffective, or 110 
creates untoward side effects, the number of viable alternatives for pain management is 111 
limited.  Lidocaine is an amide local anesthetic as well as a Class 1B antiarrhythmic agent.  It 112 
is known to block nerve conduction via sodium channels on sensory neurons and inhibit G 113 
protein-coupled receptors and NMDA receptors, giving it analgesic, anti-hyperalgesic and 114 
anti-inflammatory actions.  By inhibiting individual sodium channels, the inward sodium 115 
current is reduced, thus impeding transmission of pain impulses to the central nervous 116 
system.   With rising lidocaine concentrations, neural transmission is increasingly diminished, 117 
eventually inhibiting sensory and motor function to the point of surgical analgesia and 118 
clinical motor blockade. Local injections, epidural administration, and nerve blocks achieve 119 
high regional concentrations while diminishing risks of systemic toxicity and CNS 120 
depression. However, systemic administration can also reduce neural transmission in 121 
circumstances where regional administration is not practical.[6]  In many circumstances, it 122 
can be systemically administered at doses that effectively reduce pain and nociceptive 123 
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a steep dose-response curve such that minimal increases in dose result in large increases in 125 
pain relief.[3]   126 
In several reports in the adult literature, lidocaine has proven to be effective in chronic 127 
pain management for opioid-refractory pain.[2,10,15,16]  Lidocaine infusions have also been 128 
useful in ameliorating daily and migraine headaches in adult patients.[5]  And in adult 129 
patients afflicted with various oncologic diagnoses, Sharma et al demonstrated that 130 
intravenous lidocaine was effective in reducing pain scores.[16]  Interestingly, Schwartzman 131 
et al reported that a cohort of complex regional pain syndrome patients enjoyed improved 132 
pain control for three months following a five day infusion of lidocaine.  This implies that 133 
lidocaine may partially “reset” dysregulated pain pathways. 134 
Recently, the use of lidocaine therapy for pain management in the pediatric 135 
population has been documented.  Lidocaine infusions helped control refractory pain in case 136 
reports of pediatric patients with cancer and primary erythromelalgia.[7,13]  Additionally, 137 
lidocaine infusions were effective in managing pain in a series of adolescent and young adult 138 
patients suffering from headaches and neuropathic pain states.[12]  139 
Since information on lidocaine infusions for refractory pain in pediatrics is 140 
underrepresented in the current literature, we aim to describe the effectiveness of CLIs used 141 
in several patients with cancer pain.  Continuous lidocaine infusions in this patient population 142 
are an important therapeutic option to consider for pediatric patients suffering from cancer-143 
related pain who have either exhausted all other classes of pain medication, or whose pain 144 
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After Institutional Review Board approval was obtained, the electronic medical 147 
records of patients who had received lidocaine infusions to manage severe, refractory pain 148 
were reviewed.  A total of four pediatric patients with diverse oncologic diagnoses resulting 149 
in longstanding refractory pain were identified.  Pain was considered refractory when dose 150 
escalations of opiates did not result in clinical improvement in pain and/or when other 151 
adjuvant therapies (eg, ketamine, gabapentin) failed to achieve pain scores tolerable to 152 
patients. Eligibility to receive lidocaine was determined by primary managing clinicians. The 153 
four patients received lidocaine infusions between January 2010 and December 2013.  During 154 
this time period, there were a total of fourteen infusions.   155 
Although care was not protocolized, all patients were admitted to the Pediatric 156 
Intensive Care Unit (PICU) to initiate the infusions, where cardio-respiratory monitoring and 157 
frequent neurological assessments were employed during initial therapy.  The institutional 158 
standard for bolusing lidocaine non-emergently is over 2-3 minutes.  If lidocaine infusion 159 
doses were stable and patients were medically stable after initiation in the PICU, infusions 160 
could be continued on the general care units.  Lidocaine infusions were delivered via an 161 
infusion pump with lidocaine infusion concentrations of 8 mg/mL.  Infusions were initiated 162 
and titrated at the discretion of the pediatric critical care team in consultation with the 163 
palliative care and acute pain service teams. 164 
Demographic data including age, sex, and weight were collected by the study 165 
members through structured chart abstraction.  Additional data collection included the 166 
following:  diagnosis, length of therapy, continuous infusion rates, loading doses used, serum 167 
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lidocaine infusion.   Patient-reported pain scores were measured on a 0-10 numeric scale (0 169 
for no pain and 10 for worst pain).    170 
Conventional descriptive and comparative biostatistical analyses were made, 171 
including correlation coefficients and Wilcoxen Rank Sum tests using cloud-based statistical 172 
software (StatCrunch by Integrated Analytics LLC). Unadjusted p values are provided in the 173 
comparisons of pain scores before, during, and after CLIs (Figure 3), and a conservative 174 
Bonferroni correction for these 6 comparisons would establish a significant p value of 175 
<0.008. 176 
Results 177 
The four patients, ages 8, 16, 17, and 18 years, received a total of fourteen infusions 178 
among them.  There were two females and two males.  All patients suffered from advanced 179 
solid tumors (teratoma, osteosarcoma, rhabdomyosarcoma, and neurofibromatosis with 180 
malignant transformation into a malignant peripheral nerve sheath tumor).  These patients 181 
had been previously treated with a multimodal approach to their longstanding pain of weeks 182 
to months – with days to weeks of acutely escalating pain severity.  They had been prescribed 183 
combinations of opioid and non-opioid medications to manage pain without satisfactory relief 184 
prior to initiation of lidocaine therapy (Table I), and two of four patients had pain features 185 
with stigmata of neuropathic pain that had partly responded to neuropathic pain agents 186 
(gabapentin, pregabalin, duloxetine).  All pain medications that patients had been taking prior 187 
to lidocaine were continued during CLIs. However, in three of four patients the total opiate 188 
dose was reduced by at least 50% during their first CLI, after which re-escalation of these 189 





This article is protected by copyright. All rights reserved. 
 
This article is protected by copyright. All rights reserved. 
 
Details of lidocaine loading doses, infusion rates, duration of infusions, and side 191 
effects noted are in Table I.  During the four years reviewed, the patients each underwent 2-8 192 
infusions with a median duration of infusion of 2.15 days (range 5 hours – 17 days).  A 193 
lidocaine loading dose of 1 mg/kg was administered in 10 of 14 (71.4%) of the infusions.  For 194 
non-emergent medication boluses prior to infusions, our institution’s standard loading 195 
procedure is over 2-3 minutes on an infusion pump. The continuous infusion doses ranged 196 
from 15-50 mcg/kg/min.  The median initial and maximum infusion rates were 30 and 36 197 
mcg/kg/min, respectively.  The infusions were titrated to either maximal pain relief or 198 
emergence of intolerable side effects. 199 
 Three of our patients experienced adverse events that could have resulted from the 200 
lidocaine infusions.  These side effects included changes in vision, visual hallucinations, and 201 
paresthesias.  These symptoms occurred in 35% (5 of 14 infusions); in all cases, the 202 
symptoms resolved either spontaneously or with decreasing the infusion rate. No patients 203 
experienced seizures or cardiac complications during their inpatient lidocaine infusions. 204 
  Serum concentrations were measured in some of the patients (3 of 4) during some of 205 
the lidocaine infusions (10 of 14) at the discretion of the primary service, palliative care, and 206 
acute pain service teams. The serum lidocaine levels ranged from 1.7 to >40.1 mcg/mL, the 207 
upper limit of quantification by the assay.  Lidocaine level data were evaluated for outliers 208 
for the purpose of this analysis, and 5 of 60 levels were excluded for being greater than 28 209 
mcg/mL (4 of them beyond measurable limits). Exclusions were done with thorough review 210 
to ensure: (1) the patients’ providers believed these to be contaminants; (2) there was a lack 211 
of correlation with changes in clinical status or management; and (3) timely repeat values 212 
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Lidocaine serum concentrations corresponding with infusion rates for patients B, C & 214 
D are displayed in the left panel of Figure 1.  There was a statistically insignificant weak 215 
correlation between increasing infusion rates of lidocaine and serum levels in all patients.  216 
The slope of the relationship between infusion rate and serum lidocaine levels varied among 217 
patients, with some having higher serum levels at the same infusion rate (data not shown).   218 
In addition, patients’ pain scores were significantly, inversely correlated with their serum 219 
lidocaine concentrations, as shown in the right panel of Figure 1, indicating that improved 220 
subjective pain scores were associated with increasing serum lidocaine concentrations. 221 
 Figure 2 summarizes the four patients’ pain scores at key points during and after their 222 
infusions.  Compared to pain scores at initiation, scores were significantly reduced 4 hours 223 
into the infusion and further significantly reduced by the end of the infusion.  In the 24 hours 224 
after cessation of the lidocaine infusion, pain scores rebounded slightly, but non-significantly, 225 
and remained significantly lower than pain scores at initiation (Figure 2).  Absolute pain 226 
score reduction was greater for severe versus moderate pain states prior to lidocaine therapy, 227 
but similar in proportional reduction.  Episodes with pain scores of 8-10 at initiation of 228 
therapy (n=9 infusions) showed reductions in average pain score from 8.6 to 1.8, a change of 229 
-6.8 (-79%), whereas starting pain scores of 2-7 (n=5 infusions) showed average pain score 230 
reduction from 4.4 to 0.6, a change of -3.8 (-86%). All patients received more than one CLI, 231 
with repeat infusions predicated on the clinical impression that they responded favorably to a 232 
prior CLI (one in home hospice, not included in this analysis). 233 
The left panel of Figure 3 graphically depicts the four patients’ pain scores at the 234 
initiation of lidocaine infusion, four hours after initiation, and the termination of the infusion 235 
for all fourteen infusions.  The difference in pain scores between the initial pain score and 236 
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initiation and termination pain scores are all statistically significant.  The right panel of 238 
Figure 3 depicts time point including the 24 hours after termination of the infusion, in the 239 
patients in whom these data were available.  The reported pain scores were largely unchanged 240 
in the 24 hours after termination of the infusion. Documentation of pain scores after 24 hours 241 
was sparse; however in one series from each of the four patients, reduced pain scores were 242 
identified between 2 days and 4 months off lidocaine (Table II).  243 
Discussion 244 
Opioids are usually the first-line pharmacologic agents for moderate to severe pain, 245 
but in some instances neuropathic and oncologic pain can be opioid-refractory and 246 
challenging to manage.  Our series describes four patients suffering from malignant pain as 247 
result of invasive solid tumors in various anatomic locations who underwent a total of 248 
fourteen lidocaine infusions. This therapy was well-tolerated and markedly reduced pain 249 
scores for at least 24 hours after cessation, and occasionally much longer periods. 250 
Data have shown that the analgesic response to intravenous lidocaine is characterized 251 
by a precipitous "break in pain" over a narrow dosage and concentration range for a given 252 
patient.[3] Prior studies of intravenous lidocaine have also found that symptoms of toxicity 253 
develop in a reasonably sequential and predictable manner based on serum lidocaine 254 
levels(Table III).[7]  The early expected toxicities (lightheadedness, sensorium disturbances) 255 
for a relatively short/finite infusion time were preferable to inadequately controlled pain, so 256 
the approach employed was titration of lidocaine infusions either to a pain score of zero or 257 
emergence of early, tolerable toxicities. As these patients were managed in an ICU where 258 
benzodiazepine therapy was readily available, infusions were titrated to achieve adequate 259 
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This was directed by patient priorities, in an effort to balance pain management and the side 261 
effect profile of intravenous lidocaine therapy, which is known to cause seizures at higher 262 
serum levels (Table III).  This approach may not be advisable in patients who either would 263 
not prioritize pain management over the emergence of seizures or even more serious side 264 
effects, or in patients receiving therapy on the ward or at home, where treatment of seizures 265 
may be difficult.  In our series of fourteen infusions, there were no seizures noted during 266 
lidocaine therapy.   267 
Due to a paucity of information on the safety of this therapy in the pediatric setting, 268 
the initial CLI for each patient was started in the PICU where the intensive care, palliative 269 
care and acute pain service teams collaborated.  These infusions were initiated for high pain 270 
scores reported by patients, which were not responsive to escalating opioids or other 271 
treatments, including adjuvant non-opioid agents such as ketamine, gabapentin, and steroids.  272 
In all cases, the patients’ pain scores were lower during and immediately after the lidocaine 273 
infusion.  In some cases, the effect was more dramatic and prolonged than in others, but as 274 
became evident with retrospective chart review, the patients’ pain scores were not assessed at 275 
scheduled intervals, complicating structured analyses and long term follow-up.  Interestingly, 276 
subjective pain scores were more dramatically decreased when the patients reported higher 277 
scores prior to therapy.  This is consistent with previously published studies which 278 
demonstrated that the magnitude of the response to therapy correlated with the degree of pain 279 
intensity at the start of therapy.[2,12] 280 
A significant safety concern with systemic lidocaine administration is risk of seizures, 281 
relating to both a direct effect and that of the predominant hepatic metabolite 282 
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dysfunction. There is also concern regarding the pharmacokinetics of amino-amides (e.g., 284 
lidocaine and bupivacaine) in neonates and infants, and members of these age groups were 285 
not represented in our series.  Due to reduced metabolic clearance and protein binding, 286 
neonates and infants can develop drug and metabolite accumulation and resultant toxicity 287 
during administration of these medications.[8]  However, among the 8-18 year old patients 288 
we describe, the lidocaine infusion therapy was well tolerated. Side effects observed were 289 
primarily paresthesias, blurry vision and visual hallucinations, but in all cases were preferable 290 
to the patients than the uncontrolled pain.  Two patients had episodes of paresthesias during 291 
therapy.  Patient C had paresthesias in the right lower extremity during the first lidocaine 292 
infusion, which may have been due to the primary disease process, as the patient was 293 
experiencing similar symptoms on admission prior to therapy.  During this patient’s eighth 294 
infusion, tingling was reported when the lidocaine infusion was increased from 32 to 35 295 
mcg/kg/min.  This symptom resolved when the infusion was reduced to 32 mcg/kg/min and 296 
maintained at this rate.  Patient B reported blurry vision and visual hallucinations during the 297 
third infusion, however this patient was receiving adjuvant analgesic ketamine and high dose 298 
dexamethasone at the time, which may have been contributory, as the infusion rate was not 299 
changed, and the symptom spontaneously resolved. 300 
Serum lidocaine concentrations were not reliably correlated with infusion rates, and 301 
the degree of serum lidocaine concentration increase as a result of infusion rate varied among 302 
patients.  For example, patient B had concentration s of 6-7 mcg/mL when receiving an 303 
infusion of 35 mcg/kg/min, whereas patient C had concentrations of 2.5-3.5 mcg/mL during 304 
an infusion of 33 mcg/kg/min.  It is likely that organ function, drug interactions, and other 305 
comorbidities affect the serum concentrations in individual patients.  Patient pain scores 306 
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weak.  Because of both inter-individual variability in metabolism and tolerance, titrating 308 
infusion to effect and monitoring serum lidocaine levels to define a particular patient’s 309 
therapeutic window may be more useful than predefined infusion ranges and toxicity 310 
thresholds. In contrast to intravenous lidocaine’s use as an antiarrhythmic, the individualized 311 
approach used in these children with uncontrolled pain and, ultimately, terminal cancers is 312 
consistent with palliative care models – carefully balancing risks and benefits.  It should be 313 
emphasized that pain management was of utmost priority for these specific patients, and 314 
therefore infusions were maintained and adjusted with this as the primary goal.  A more 315 
conservative approach may be necessary for patients who are not at end of life, or in whom 316 
the emergence of side effects is unsettling or undesirable. 317 
As reported in previous literature, several of the study patients’ analgesic benefit 318 
persisted days to months beyond the termination of the lidocaine infusion.[1,12]  This is an 319 
interesting phenomenon, given that the half-life of lidocaine is 90-120 minutes.  The direct 320 
pharmacologic action of lidocaine would have been terminated soon after discontinuing the 321 
infusions, suggesting that lidocaine exhibits unconventional pharmacodynamics on 322 
longstanding or wound-up pain.  Further research may clarify the mechanism of this 323 
prolonged clinical benefit observed in some patients. It may relate to interrupting 324 
sensitization or intensified pain from positive feedback loops, or alternately by mitigating 325 
opiate induced hyperalgesia. Lidocaine’s impact on complement and proinflammatory 326 
cytokines may also contribute to pain modulation.[9] Ultimately, some of the effect may not 327 
be specific to lidocaine per se, but rather relate to an effective interruption of the physiology 328 
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 Of note, one of our patients who did not tolerate weaning of the lidocaine infusion 330 
(i.e. did not experience the sustained, post-infusion relief) was successfully transitioned to an 331 
oral sodium channel blocker, mexiletine, making it feasible to discharge him from the 332 
hospital without an ongoing intravenous therapy.  Successful transition from lidocaine 333 
infusion to oral mexilitine has previously been reported in the adult literature.[4]  Thus, this 334 
may present a viable outpatient option for patients in whom intravenous lidocaine is effective 335 
in providing opiate-refractory analgesia but whose benefits appear to be from the direct 336 
mechanism of the sodium channel blockade. 337 
Limitations of this case series analysis include its retrospective design, small sample 338 
size and absence of pediatric patients less than 8 years of age.  It is inadequately powered to 339 
reliably detect adverse complications, but is consistent with the safety profile of lidocaine 340 
reported in other studies. Strengths of this analysis include applicability across a wide range 341 
of cancer diagnoses, reproducibility within and among patients, and objective 342 
pharmacokinetic data corroborating the subjective patient-reported outcome measure of pain. 343 
Overall, this review indicates that lidocaine infusion therapy was a well-tolerated and 344 
useful adjuvant for these pediatric patients with cancer pain refractory to conventional and 345 
even other non-conventional, second and third tier therapies like steroids, gabapentin, 346 
ketamine, and cannabinoids.  This therapy was associated with some side effects that were 347 
tolerable, and infusions were able to be transitioned to non-ICU settings.  Given the relative 348 
inexperience with continuous intravenous lidocaine therapy for this indication in pediatrics, 349 
and because of the complex multidisciplinary, multiprofessional care coordination required, 350 
our institution subsequently developed a clinical practice guideline (Supplemental Appendix). 351 
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our institution and was based on the general approaches successfully used in these patients 353 
and described in the published literature.  Further clinical studies are warranted to better 354 
describe the therapeutic role, safety, and optimal management of intravenous lidocaine 355 
infusions for treatment of opioid-refractory pain in the pediatric population as well as its 356 
potential application in more diverse pain syndromes among children. 357 
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Figure 1.  The left panel shows the scatter plot and best fit trend-line of serum lidocaine level 
versus lidocaine infusion rate (triangles). The right panel shows the scatter plot and best fit 
trend-line of serum lidocaine level versus patient-rated pain scores (diamonds), with a 
statistically significant, moderately negative correlation coefficient. 
 
Figure 2.  The four leftmost panels represent the four patients (A-D) with pain ratings during 
the 14 individual lidocaine infusions (gray lines) and an average of all responses for that 
patient (heavy black lines). Pain ratings are recorded at initiation (START) of the lidocaine 
infusion, 4 hours into the infusion (4 HRS), and at the termination (END), although this time-
point varied between infusions from 6 hours to 17 days. The rightmost pane represents the 7 
individual lidocaine infusions where documented pain scores were available for the 24 hours 
after cessation of the lidocaine infusion, and the highest pain score recorded in that 24 hours 
without lidocaine (gray shaded) is noted (24 HRS). 
Figure 3.  The left boxplot shows pain ratings during the 14 individual lidocaine infusions for 
all 4 patients (A-D). The right boxplot shows pain ratings during and after the 7 individual 
lidocaine infusions in 3 patients (B-D) where documented pain scores were available for the 
24 hours after cessation of the lidocaine infusion (the highest pain score recorded in that 





Supplemental Appendix.  Clinical Practice Guideline for Intravenous Lidocaine Therapy at 
UMHS. 
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10 3   4 at 4 
months 
B 
4 2                 
0 at 6 
days 
C 
9 4 2 at 2 
weeks 
D 
7 0                 
0 at 2 
days 
 365 
Table III.  Serum lidocaine levels and symptoms of toxicity 366 
Lidocaine level (mcg/mL) Symptoms 
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8 Visual/auditory disturbances, dissociative effects, 
muscle twitching, hypotension 
12 Convulsions 
16 Coma 
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